PROTEOMICS AND METABOLOMICS SHARED RESOURCE Project Summary The Bioanalytical Laboratory Shared Resource scored as ?excellent? during the previous review. To reflect the evolving needs of Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) members, it has since been restructured to form the Proteomics and Metabolomics Shared Resource (PMSR). This Shared Resource provides advanced mass spectrometry services, technologies, and scientific consultation for global and targeted proteomics, metabolomics and lipidomics studies. The PMSR specializes in discovery, identification, characterization, and quantification of biomolecules, including proteins, lipids and other metabolites by mass spectrometry and biochemical methods in a variety of biological specimens; chromatography of proteins, peptides, lipids, nucleic acids and chemical compounds; measurement of bioenergy metabolism; and targeted multiplex analysis using immunoassays. Assets of PMSR include 1) Three major mass spectrometry systems for metabolomics and lipidomics analysis, including a new Shimadzu LCMS-8050 LC/MS/MS System; 2) A newly-installed Thermo Q-Exactive HF mass spectrometer with data-independent acquisition and parallel reaction monitoring capabilities interfaced with a nanoLC system for proteomics analysis; 3) Access to a broad range of instruments and expertise at RTI Metabolomics, now part of a broad partnership with the WFBCCC and PMSR; and 4) Expertise of personnel. The PMSR is directed by Cristina M. Furdui, Ph.D., and Mark O. Lively, Ph.D., and currently employs four individuals (Jingyun Lee, Ph.D, Hanzhi Wu, Ph.D., Brian Fulp, B.S., and Mark Morris, B.S.) for a combined total of 2.7 FTE (1.15 CCSG FTEs requested). During the last full reporting year (11/1/2014 ? 10/31/2015), the PMSR supported the research of 24 faculty members of Wake Forest Baptist Medical Center and 6 external researchers, analyzing 2,116 samples (approximately 90% of PMSR capacity). Usage by WFBCCC members with peer-reviewed funding during this period was 47% (75% based on number of samples). The Institution's support of the PMSR is reflected in its investment of close to $1M for purchasing of new instrumentation and hiring of additional personnel, a significant cost-sharing that increases the value of the CCSG investment in PMSR. The Shared Resource is reviewed annually by the Institution's Centers and Cores Advisory Committee, which is within Biomedical Research Services and Administration, and reports to the Dean. In addition, quarterly meetings of the Shared Resource Directors are held and include reports/discussions on activity, best practices, enhanced capabilities, and administrative management techniques. These are chaired by Kounosuke Watabe, Ph.D., the Associate Director for Shared Resources. The WFBCCC Senior Leadership has the final responsibility for evaluating the effectiveness of PMSR in supporting the Cancer Center mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-46
Application #
10092993
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-02-01
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Holmila, Reetta J; Vance, Stephen A; Chen, Xiaofei et al. (2018) Mitochondria-targeted Probes for Imaging Protein Sulfenylation. Sci Rep 8:6635
Feliz-Mosquea, Yismeilin R; Christensen, Ashley A; Wilson, Adam S et al. (2018) Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. Breast Cancer Res Treat 172:69-82
Li, X C; Wang, M Y; Yang, M et al. (2018) A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Ann Oncol 29:938-944
Rego, Stephen L; Harvey, Scott; Simpson, Sean R et al. (2018) TREX1 D18N mice fail to process erythroblast DNA resulting in inflammation and dysfunctional erythropoiesis. Autoimmunity :1-12
Lu, Yong; Wang, Qiang; Xue, Gang et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell 33:1048-1060.e7
Godwin, Ryan C; Macnamara, Lindsay M; Alexander, Rebecca W et al. (2018) Structure and Dynamics of tRNAMet Containing Core Substitutions. ACS Omega 3:10668-10678
Peak, Taylor C; Praharaj, Prakash P; Panigrahi, Gati K et al. (2018) Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells. Biochem Biophys Res Commun 499:1004-1010
Akter, Salma; Fu, Ling; Jung, Youngeun et al. (2018) Chemical proteomics reveals new targets of cysteine sulfinic acid reductase. Nat Chem Biol 14:995-1004
Han, Fei; Li, Chien-Feng; Cai, Zhen et al. (2018) The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun 9:4728
Chmielewski, Jeffrey P; Bowlby, Sarah C; Wheeler, Frances B et al. (2018) CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Mol Cancer Res 16:1687-1700

Showing the most recent 10 out of 548 publications